S
24.02
-0.33 (-1.36%)
| 前收盘价格 | 24.35 |
| 收盘价格 | 24.21 |
| 成交量 | 438,442 |
| 平均成交量 (3个月) | 553,595 |
| 市值 | 1,436,336,000 |
| 价格/销量 (P/S) | 650.22 |
| 股市价格/股市净资产 (P/B) | 7.32 |
| 52周波幅 | |
| 利润日期 | 26 Feb 2025 - 3 Mar 2025 |
| 稀释每股收益 (EPS TTM) | -37.90 |
| 总债务/股东权益 (D/E MRQ) | 0.06% |
| 流动比率 (MRQ) | 7.32 |
| 营业现金流 (OCF TTM) | -151.25 M |
| 杠杆自由现金流 (LFCF TTM) | -60.86 M |
| 资产报酬率 (ROA TTM) | -38.80% |
| 股东权益报酬率 (ROE TTM) | -91.62% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Spyre Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.6
| 分析师共识 | 3.5 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -4.0 |
| 平均 | 0.63 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 8.80% |
| 机构持股比例 | 88.77% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 65.00 (Baird, 170.61%) | 购买 |
| 65.00 (Guggenheim, 170.61%) | 购买 | |
| 中 | 65.00 (170.61%) | |
| 平均值 | 65.00 (170.61%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 33.90 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Baird | 13 Nov 2024 | 65.00 (170.61%) | 购买 | 32.98 |
| Guggenheim | 25 Oct 2024 | 65.00 (170.61%) | 购买 | 34.81 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合